title: Protective effect of tetrahydrocurcumin against cisplatin-induced renal damage: in vitro and in vivo studies.
abstract: The adverse effects of anticancer drugs can prompt patients to end their treatment despite the efficacy. Cisplatin is a platinum-based molecule widely used to treat various forms of cancer, but frequent and long-term use of cisplatin is limited due to severe nephrotoxicity. In the present study, we investigated the protective effect and mechanism of tetrahydrocurcumin on cisplatin-induced kidney damage, oxidative stress, and inflammation to evaluate its possible use in renal damage. Cisplatin-induced LLC-PK1 renal cell damage was significantly reduced by tetrahydrocurcumin treatment. Additionally, the protective effect of tetrahydrocurcumin on cisplatin-induced oxidative renal damage was investigated in rats. Tetrahydrocurcumin was orally administered every day at a dose of 80 mg/kg body weight for ten days, and a single dose of cisplatin was administered intraperitoneally (7.5 mg/kg body weight) in 0.9 % saline on day four. The creatinine clearance levels, which were markers of renal dysfunction, in cisplatin-treated rats were recovered nearly back to normal levels after administration of tetrahydrocurcumin. Moreover, tetrahydrocurcumin exhibited protective effects against cisplatin-induced oxidative renal damage in rats by inhibiting cyclooxygenase-2 and caspase-3 activation. These results collectively provide therapeutic evidence that tetrahydrocurcumin ameliorates renal damage by regulating inflammation and apoptosis.
authors.affiliation: Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Korea.
authors.forename: Kyung Il
authors.initials: KI
authors.lastname: Song
authors.affiliation: College of Korean Medicine, Gachon University, Seongnam, Korea.
authors.forename: Jun Yeon
authors.initials: JY
authors.lastname: Park
authors.affiliation: Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, Korea.
authors.forename: Seungyong
authors.initials: S
authors.lastname: Lee
authors.affiliation: College of Korean Medicine, Gachon University, Seongnam, Korea.
authors.forename: Dahae
authors.initials: D
authors.lastname: Lee
authors.affiliation: Department of Surgery, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Korea.
authors.forename: Hyuk-Jai
authors.initials: HJ
authors.lastname: Jang
authors.affiliation: Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, Korea.
authors.forename: Su-Nam
authors.initials: SN
authors.lastname: Kim
authors.affiliation: Laboratory of Molecular Oncology, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea.
authors.forename: Hyeonseok
authors.initials: H
authors.lastname: Ko
authors.affiliation: Department of Food Science, Gyeongnam National University of Science and Technology, Jinju, Korea.
authors.forename: Hyun Young
authors.initials: HY
authors.lastname: Kim
authors.affiliation: Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, Korea.
authors.forename: Jae Wook
authors.initials: JW
authors.lastname: Lee
authors.affiliation: College of Korean Medicine, Gachon University, Seongnam, Korea.
authors.forename: Gwi Seo
authors.initials: GS
authors.lastname: Hwang
authors.affiliation: College of Korean Medicine, Gachon University, Seongnam, Korea.
authors.forename: Ki Sung
authors.initials: KS
authors.lastname: Kang
authors.affiliation: College of Korean Medicine, Gachon University, Seongnam, Korea.
authors.forename: Noriko
authors.initials: N
authors.lastname: Yamabe
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D030024:Curcuma / Q000737:chemistry*; D003474:Curcumin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051546:Cyclooxygenase 2 / Q000378:metabolism; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism / Q000517:prevention & control*; D018374:LLC-PK1 Cells; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D017208:Rats, Wistar; D013552:Swine
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000975:Antioxidants; D015415:Biomarkers; D010936:Plant Extracts; C096277:tetrahydrocurcumin; D051546:Cyclooxygenase 2; D053148:Caspase 3; D003474:Curcumin; D002945:Cisplatin